After finishing at $1.19 in the prior trading day, Biora Therapeutics Inc (NASDAQ: BIOR) closed at $1.27, up 6.72%. In other words, the price has increased by $+0.0800 from its previous closing price. On the day, 556421 shares were traded.
Ratios:
Our goal is to gain a better understanding of BIOR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.28 and its Current Ratio is at 0.28.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOR now has a Market Capitalization of 32.24M and an Enterprise Value of 102.06M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1727.83. Its current Enterprise Value per Revenue stands at 5.67k whereas that against EBITDA is -0.92.
Stock Price History:
Over the past 52 weeks, BIOR has reached a high of $6.70, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is 1.0717, while the 200-Day Moving Average is calculated to be 2.3650.
Shares Statistics:
The stock has traded on average 425.00K shares per day over the past 3-months and 839.94k shares per day over the last 10 days, according to various share statistics. A total of 27.21M shares are outstanding, with a floating share count of 24.50M. Insiders hold about 9.96% of the company’s shares, while institutions hold 47.69% stake in the company. Shares short for BIOR as of Feb 15, 2024 were 714.57k with a Short Ratio of 1.68, compared to 592.33k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.63% and a Short% of Float of 2.79%.
Earnings Estimates
Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$0.59 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.74, while EPS last year was -$0.75. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$7.78 and -$8.39 for the fiscal current year, implying an average EPS of -$8.08. EPS for the following year is -$2.05, with 2 analysts recommending between -$1 and -$3.11.
